Eton Pharmaceuticals, Inc.
Key statistics
from XBRL data in SEC filingsAI briefing
from the latest 10-K, 10-Q and 8-K eventsEton Pharmaceuticals is a rare disease pharmaceutical company with eight commercial products and five late-stage candidates, now generating record revenues from its pediatric endocrinology and metabolic franchises.
What they do
Eton develops and commercializes treatments for rare diseases, with a focus on pediatric endocrinology and metabolic disorders. Its commercial portfolio includes INCRELEX, ALKINDI SPRINKLE, KHINDIVI, GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone, plus the relaunched HEMANGEOL. The company also has late-stage candidates including ET-600, Amglidia, ET-700, ET-800, and ZENEO hydrocortisone autoinjector.
Revenue drivers
- HEMANGEOL — Relaunched May 1, 2026; contributed to record Q2 2026 revenues with approximately 95% of existing patients transitioned by end of June.
- Pediatric endocrinology franchise — Includes ALKINDI SPRINKLE, KHINDIVI, and INCRELEX; adrenal franchise surpassed 600 active patients, and INCRELEX drove strong growth via dose optimization.
- Metabolic products — Includes GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone; all posted strong year-over-year growth in Q2 2026.
Recent performance
Q2 2026 revenue was $37.6 million, up 99% from $18.9 million in Q2 2025. Fully diluted GAAP EPS was $0.35, non-GAAP EPS $0.43, and adjusted EBITDA was $16.2 million. For the first half of 2026, quarterly revenue has risen from $24.3 million in Q1 to $37.6 million in Q2. The company generated $10.5 million operating cash flow in 2025 and had $26.8 million cash at June 30, 2026.
Strategy
Eton is expanding its rare disease portfolio through acquisitions and in-licensing, such as ASN-001 and IMPAVIDO, and relaunched HEMANGEOL to leverage its commercial infrastructure. It continues to invest in its pediatric endocrinology franchise, including a Prior Approval Supplement to expand KHINDIVI's indication. The company is preparing for a potential ET-600 launch in early 2026 and plans to submit an NDA for ASN-001 in the second half of 2027.
Risks
- Medicare price negotiation — The Inflation Reduction Act could subject Eton's products to price negotiation or inflation rebates, affecting realized prices and demand.
- Concentration in rare disease markets — Many products target small patient populations (e.g., <500 for Nitisinone, <2,000 for Betaine), making revenue sensitive to patient counts and market access.
- Dependence on pipeline approvals — Late-stage candidates like ET-600 and ASN-001 require FDA approval; any delays or failures could hurt growth prospects.
- Integration and execution risk — Recent acquisitions (HEMANGEOL, ASN-001, IMPAVIDO) require successful integration and commercialization to meet revenue guidance.
Outlook
Management raised 2026 revenue guidance to exceed $145 million, up from prior guidance of more than $120 million, and expects adjusted EBITDA margin of at least 35%. They anticipate ET-600 approval and launch shortly after its PDUFA date of February 25, 2026, and potential KHINDIVI expanded indication approval in H1 2027. ASN-001 NDA submission is expected in the second half of 2027.